Objectives: To estimate the clinical and economic trade-offs involved in using the molecular assay EPICUP to aid in identifying the primary site in Cancer of Unknown Primary (CUP). MethOds: A decision-analytic model was developed to estimate the lifetime clinical and economic outcomes of incorporating the EPICUP assay compared with other molecular assays (CancerTYPE ID, Cancer Origin Test and ResponseDX: Tissue of Origin Test). The analysis was limited to 6 primary cancer sites (breast, colon, pancreas, lung, liver and prostate) for adenocarcinoma histological subtype. Results are presented as incremental cost-effectiveness ratio (ICER, cost per quality-adjusted life-years [QALY] gained) from the USA Health Payers perspective. Model inputs were based on a case-control study of EPICUP, published literature, Surveillance Epidemiology and End Results database and a clinical expert panel. Results: Based on a price of USD3,500 for EPICUP and for a willingness to pay USD100,000, EPICUP is cost-effective (vs. CancerTYPE ID, Cancer Origin Test and ResponseDX: Tissue of Origin Test) in all tumors analyzed, ranging between 80% and 100% of the simulations. EPICUP increased the proportion of patients treated correctly, decreased the proportion of patients treated with an empiric approach, and increased the quality-adjusted overall survival. For a willingness to pay USD50,000 EPICUP is cost-effective in breast, colon, pancreas, lung (NSCLC) and prostate cancer, again ranging between 80% and 100% of the simulations. These findings were robust across deterministic and probabilistic sensitivity analyses. cOnclusiOns: EPICUP assay for diagnosing the primary tumor in CUP patients is a cost-effective approach in breast, colon, pancreas, lung (NSCLC), hepatocellular and prostate cancer in comparison with other alternatives available, while improving patient care.
Objectives: To assess the health effectiveness, cost and cost-effectiveness of different oral anticoagulation therapies in China including warfarin plus International Normalized Ratio (INR) test in hospital labs (Lab test), warfarin plus patient self-test (PST) with point of care device, and novel anticoagulant (Dabigatran) alone. MethOds: A Markov model containing four states (no complication, haemorrhagic event, thrombotic event and death) was developed to account for long term cost and outcomes of warfarin/novel anticoagulant users including atrial fibrillation patients and deep venous thrombosis patients. Only direct medical cost was taken into consideration, covering expenses of drugs, OAT monitoring and complication management. Both clinical and economic parameters were mainly derived from literatures. Results: The hospital lab test pattern achieved 7.46 LYs and 4.43 QALYs with a total cost of CNY 28, 277 (USD 4, 561) , while the PST pattern obtained a prolonged 8.79 LYs and 5.30 QALYs with the larger amount of cost, CNY 45, 992 (USD 7, 418) . Comparably, the novel anticoagulant pattern acquired 8.08 LYs and 4.87 QALYs and the cost was significant higher reaching CNY 99,545 (USD 16,056), dominated by PST pattern due to shortened QALYs while increased cost. The ICER of PST versus hospital lab test came to CNY 20,363 (USD 3,284) per QALY gained, lower than China GDP per capita in 2014 (CNY 42, 900) . Sensitivity analysis demonstrated the results were not sensitive to main indicators, including utility in different health status, complication probability and disease management cost. cOnclusiOns: Compared with OAT management in hospital laboratory, PST can generate more QALYs by reducing the risk of major thrombotic and bleeding events with acceptable incremental cost, which turns to be the most cost effective among the 3 patterns and demonstrates promising future in OAT management.
PMD71 EconoMic AnAlysis of EPicuP, An EPigEnEtic tEst to PrEDict thE tissuE of origin in cAncEr of unknown PriMAry sitE, froM thE sPAnish nhs PErsPEctivE
Gracia A 1 , Balañá C 2 , Kaskens L 1 , Chiavenna S 3 , Matias-Guiu X 4 , Rubio-Rodríguez D 5 , Rubio-Terrés C 5 , Iglesias L 6 , Esteller M 7 1 HEOR & MA Dpt Ferrer, Barcelona, Spain, 2 Medical Oncology Dpt, ICO, Badalona, Spain, 3 Ferrer Advanced Biotherapeutics, Barcelona, Spain, 4 IRB, Lleida, Spain, 5 Health Value, Madrid, Spain, 6 Medical Oncology Dpt, 12 de Octubre Hospital, Madrid, Spain, 7 IDIBELL, Barcelona, Spain Objectives: To estimate the clinical and economic trade-offs involved in using the molecular assay EPICUP to aid in identifying the primary site in Cancer of Unknown Primary (CUP). MethOds: A decision-analytic model was developed to estimate the lifetime clinical and economic outcomes of incorporating the EPICUP assay compared with standard care and other molecular assays (CancerTYPE ID, Cancer Origin Test and ResponseDX: Tissue of Origin Test). The analysis was limited to 6 primary cancer sites (breast, colon, pancreas, lung, liver and prostate) for adenocarcinoma histological subtype. Results are presented as incremental cost-effectiveness ratio ( Objectives: To develop an economic evaluation to compare individually and vialpackaged strips for glucose monitoring. MethOds: A simple decision tree model was developed using Excel to compare the costs of using individual vs. vial-packaged strips in a hospital setting. The decision tree described costs and consequences associated with two main parameters: risk of nosocomial infection due to the contamination of strips and risk of hypoglycemia/hyperglycemia due to an error in the determination of glycemia induced by the storage conditions of the strips. For each alternative (IP and VP), a simulated cohort of 1000 patients went through the tree accounting for costs and effects, and the results were expressed as hypoglycemic events, nosocomial infection events, use/waste of strips and ICER. Sources of parameters is wide and uncertainty is high. Due to the lack of information about certain parameters, a group of assumptions were made .The risk of measurement error using contaminated strips was modelled to account for hypoglycaemic events. Uncertainty was tested using one-way sensitivity analysis (OWSA) and probabilistic sensitivity analysis (PSA). Cost-effectiveness acceptability curve with a threshold of 25.000€ /QALY was drawn. Probabilistic results were depicted using a CE plane. Results: Individual packaged strips save money (1,162 € per patient) and get more QALYs (0.023 per patient), which confers a dominant position to individual packaged strips with 11% less nosocomial events, 10 times less hypoglycemic events (53 vs 655) and 6% reduction in the use of strips. PSA shows results in the same direction with a 64% probability of being costeffective under a threshold of 25,000 € (from 82% at 0 € and keeping the difference over 25,000 € ). cOnclusiOns: Under the assumption of wrong measurements due to bad storage conditions, the use of individual packaged strips is a dominant option over vial-packaged strips, reducing costs by a 25%.
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Objectives: To compare the effectiveness and costs in the Colombian setting (and estimate the incremental cost-effectiveness ratio ICER) of the most commonly used schemes for screening and diagnosis of type 2 diabetes mellitus in local adult population. MethOds: We evaluated four possible schemes, all involved fasting blood sugar test, two with and two without previous screening with the FINDRISC scale; and, in a second step, using either the oral glucose tolerance, or glycosylated hemoglobin tests, for confirmation of diagnosis. We designed a decision tree model with correctly identified cases as the main effectiveness outcome (estimated for Colombia from a global systematic literature review). Direct medical costs were estimated from the third party payer perspective (healthcare system), in Colombian pesos for 2014 (1 € = COP 2,660). Base cases, analyzed and validated by multidisciplinary expert panel, were used for resource estimation. Official cost databases and tariff manuals were then applied to estimate costs. No discount rates were applied. Univariate and probabilistic sensitivity analyses were performed. Results:
The schemes that used glycosylated hemoglobin test for confirmation were dominated. For a cohort of 1,000 people, the strategy of FINDRISC plus fasting blood sugar test plus oral glucose tolerance reported 969 correctly identified cases with a total cost of € 7,306; while fasting blood sugar test plus oral glucose tolerance detected 983 at a cost of € 10,880. Comparing these two schemes, the incremental cost effectiveness ratio is € 255. Sensitivity analyses did not significantly affect the results. cOnclusiOns: This study suggests that the scheme FINDRISC plus fasting blood sugar test plus oral glucose tolerance is the most appropriate strategy for screening and diagnosis of type 2 diabetes in Colombia.
PMD68 A Pct-AlgorithM to guiDE Antibiotic thErAPy in PAtiEnts hosPitAlizED with coPD ExAcErbAtions lEADs to nEt cost sAvings by rEDucing frEquEncy AnD DurAtion of Antibiotic usE As coMPArED to currEnt PrActicE
Van der Maas M 1 , Steuten L 2 1 Panaxea B.V., Enschede, The Netherlands, 2 Fred Hutchinson Cancer Research Center / University of Washington & Panaxea bv, Seattle, WA, USA Objectives: Antibiotics are often recommended as treatment for patients with COPD exacerbations. However, in many cases COPD exacerbations are not caused by a bacterial inflammation and antibiotics are prescribed unnecessary. Procalcitonin (PCT) is a biomarker with good specificity to distinguish bacterial from non-bacterial inflammations. It can prevent unnecessary antibiotic prescriptions and reduce duration of antibiotic therapy. The goal of this study is to compare the health and economic consequences of using a PCT-algorithm compared to current practice in hospitalized patients with COPD exacerbations. MethOds: A decision tree was developed, comparing the expected costs and effects of the PCT-algorithm to current practice in the UK, Germany and the Netherlands. The time horizon of the model captures the length of hospital stay and a societal perspective was adopted. Model input data are based on a systematic literature research, country specific cost data sources and expert opinions. The primary health outcome was the duration of antibiotic therapy; the incremental cost-effectiveness ratio was defined as the incremental costs per antibiotic day avoided. Results: Using a PCT-algorithm is expected to be cost-saving and more effective compared to current practice in all three countries. The incremental cost savings per antibiotic day avoided range from € 125 in Germany and € 90 in the Netherlands, to € 52 in the UK. Probabilistic sensitivity analyses showed that the PCT-algorithm tends to dominate current practice, though decision uncertainty remains (Germany: 58%, UK: 57%, the Netherlands: 58%). Duration of hospital stay at baseline is the driver of the expected cost-savings in all three countries while reduction in antibiotic days drives the incremental effectiveness of the PCT-algorithm. cOnclusiOns: A PCT-algorithm is a cost-effective way to guide the initiation and duration of antibiotic therapy when compared to current practice in COPD patients hospitalized with an exacerbation.
